Danielle Corrigan

[Proceedings of the National Academy of Sciences of the United States of America] Using an aggressive mouse ovarian tumor model, scientists found that combined oral FAK inhibitor plus function-blocking TIGIT antibody immunotherapy reduced tumor burden, prolonged mouse survival, and led to immune cell activation and tertiary lymphoid structure formation, hallmarks of an antitumor immune response.

[Nature Communications] Investigators showed that the strength of T cell receptor signaling controlled the requirement for interleukin-2 (IL-2) signals to form a pool of memory CD8+ T cells that competitively re-expanded upon secondary antigen encounter.

[Cell Reports] The authors characterized islet antigen-specific T cells in non-obese diabetic mice lacking all three interferon receptor genes.

[Experimental & Molecular Medicine] Scientists review the current knowledge of how these peripheral signals modulate the innate immune response in the mediobasal hypothalamus and enable microglia to regulate metabolic control.

[Applied Molecular Transport, Inc.] Applied Molecular Transport, Inc. announced positive top-line Phase II results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies.

[Science Immunology] To overcome the challenges faced with CAR-T cells using donor-derived conventional CD4+ or CD8+ T cells, scientists evaluated the feasibility, safety, and efficacy of using healthy donor–derived allogeneic double-negative T cells as a CAR-T cell therapy platform.